BARCELONA, Spain — A second phase III trial supports an overall survival (OS) benefit from adding a programmed cell death ligand (PD-L1) inhibitor to standard chemotherapy compared with standard chemotherapy alone for patients with extensive stage, ...
from Google Alert - health https://ift.tt/30hQxqO
via IFTTT
0 comments:
Post a Comment